#	Pagina
attuale pagina	/open-h2020/projects/226080/index.html

Opendata, web and dolomites

ImOPac SIGNED

GemciTest: An innovative In Vitro Diagnostic for the decision-making process of pancreatic cancer treatment

Total Cost €

EC-Contrib. €

Partnership

Views

ImOPac project word cloud

Explore the words cloud of the ImOPac project. It provides you a very rough idea of what is the project "ImOPac" about.

2011 occurs patient discovery effectiveness populations dead 2020 countries death june partly choose patients which regimen 360 regimens score rate surgical blood lack gemcitest chemotherapy personalized biotech stratification pdac treatments adenocarcinoma clinical bioinformatics foundation stratify incurable always turnover recommended employees until medical signature forefront 2017 innovative limited stage 13 acobiom mortality opportunity western transcriptomics treatment french data difficulty breast began imopac 34 biomarker innovation 95 decision diagnose science 1999 mention nearly pancreatic pharmacogenomics ductal versus diagnosis 80 sme 150k 2024 decisional market usa gene thanks biomarkers invasive genomics algorithm sas expertise diagnostic action cancer 4th profiles 51k metastatic create 11 toxicities

Project "ImOPac" data sheet

The following table provides information about the project.

Coordinator	ACOBIOM Organization address address: 1682 RUE DE LA VALSIERE CAP DELTA ZAC EUROMEDECINE II city: GRABELS postcode: 34790 website: www.acobiom.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2019
Duration (year-month-day)	from 2019-12-01 to 2020-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ACOBIOM ACOBIOM Organization address address: 1682 RUE DE LA VALSIERE CAP DELTA ZAC EUROMEDECINE II city: GRABELS postcode: 34790 website: www.acobiom.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (GRABELS)	coordinator	50˙000.00

Map

Project objective

Acobiom is a French Biotech SME (SAS, 8 employees). Since its foundation, June 1999, Acobiom has always been at the forefront of medical innovation, in particular in biomarker discovery and diagnostic development, thanks to its expertise and knowledge in genomics, transcriptomics, bioinformatics, and data science.

In 2011, Acobiom began working to address the problem of pancreatic cancer.

Pancreatic cancer is currently the 4th leading cause of cancer death in Western Countries. If no action is taken, it will rise to be second in 2020. For nearly 80% of patients (~51K and ~150K in USA and EU patients in 2017), diagnosis occurs at an advanced, non-surgical stage, making them incurable. The high mortality rate, with more than 95% of patients dead at 5 years, versus 13% for breast cancer, is partly due to the difficulty to diagnose, but also because of the lack of stratification of patients and a limited choice for treatments in the current decision-making process.

There are currently three major chemotherapy regimens for the pancreatic cancer, and up until now, the decisional algorithm in metastatic pancreatic ductal adenocarcinoma (PDAC) management does not mention pharmacogenomics biomarkers, needed to stratify patient populations and to choose the best treatment with the best clinical effectiveness for a given patient. These regimens have very different toxicities profiles which factors in to which regimen is recommended.

Through ImOPac project, Acobiom aims to implement an innovative approach to improve personalized pancreatic cancer management in the decision-making process of PDAC, by using biomarkers to help in the patient stratification. This approach is the GemciTest, a non-invasive test based on an 11-gene blood signature score.

Thanks to this innovation, Acobiom has an opportunity to create an EU new market estimated at 360 M€, and leading to a 34 M€ turnover by 2024.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMOPAC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMOPAC" are provided by the European Opendata Portal: CORDIS opendata.